PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24386533-4	2011	The ability to deliver cytotoxic hyperthermia to tumors (from within individual cells) via iron oxide magnetic nanoparticles (mNP) is a promising new technology that has the ability to greatly improve the therapeutic ratio of hyperthermia as an individual modality and as an adjuvant therapy in combination with other modalities.	ferric oxide	91-101	modifier of Niemann Pick type C1	Mus musculus	126-129	
24392200-3	2011	Recent in vivo studies (rodent and human) have shown that cancer cell-specific cytotoxicity can be effectively and safely delivered via iron oxide magnetic nanoparticles (mNP) and an appropriately matched noninvasive alternating magnetic field (AMF).	ferric oxide	136-146	modifier of Niemann Pick type C1	Mus musculus	171-174	
21070026-4	2010	When a mixed suspension of 23 nm pNIPAAm-modified AuNPs was heated with pNIPAAm-coated 10 nm iron oxide magnetic nanoparticles (mNPs) in human plasma, the thermally responsive pNIPAAm directed the formation of mixed AuNP/mNP aggregates that could be separated efficiently with a magnet.	ferric oxide	93-103	modifier of Niemann Pick type C1	Mus musculus	128-131	
34110969-4	2021	In the present study, we treated peritoneal metastasis of gastric cancer with MHT using superparamagnetic iron oxide (Fe3O4) nanoparticle (SPION) coated with carboxydextran as an MNP, in an orthotopic mouse model mimicking early peritoneal disseminated disease of gastric cancer.	ferric oxide	106-116	modifier of Niemann Pick type C1	Mus musculus	179-182	
20071755-1	2010	In magnetic heating treatments, intratumorally injected superparamagnetic iron oxide nanoparticles (MNP) exposed to an externally applied alternating magnetic field generate heat, specifically at the tumor region.	ferric oxide	74-84	modifier of Niemann Pick type C1	Mus musculus	100-103	
34148497-3	2021	In the present study, superparamagnetic iron oxide nanoparticles (SPIONs), atype of MNP, were conjugated with an anti-HER2 antibody, trastuzumab and termed anti-HER2-antibody-linked SPION nanoparticles (anti-HER2 SPIONs).	ferric oxide	40-50	modifier of Niemann Pick type C1	Mus musculus	84-87	
19941323-1	2009	We have developed a magnetic resonance molecular imaging method using a novel iron-oxide contrast agent targeted towards P-selectin - MNP-PBP (magnetic nanoparticle-P-selectin binding peptide) - to image endothelial activation following cerebral ischemia/reperfusion.	ferric oxide	78-88	modifier of Niemann Pick type C1	Mus musculus	134-137	
19941323-2	2009	MNP-PBP consists of approximately 1000 PBP ligands (primary sequence: GSIQPRPQIHNDGDFEEIPEEYLQ GGSSLVSVLDLEPLDAAWL) conjugated to a 50 nm diameter aminated dextran iron oxide particle.	ferric oxide	164-174	modifier of Niemann Pick type C1	Mus musculus	0-3	
19941323-8	2009	Compared with the nontargeted iron oxide agents MNP-NH2 and Feridex, MNP-PBP showed a significantly greater T(2) effect within the infarction.	ferric oxide	30-40	modifier of Niemann Pick type C1	Mus musculus	69-72	
27274908-5	2016	Here we demonstrate that assembling of Recombinant Adenoviral vectors with suitable iron oxide MNPs into magneto-adenovectors (RAd-MNP) and further exposure to a gradient magnetic field enables to efficiently overcome transduction resistance in skeletal muscle cells.	ferric oxide	84-94	modifier of Niemann Pick type C1	Mus musculus	95-98	
25962161-3	2015	In the present study, we have synthesized magnetic (iron oxide) nanoparticles (MNP) coated with an amphiphilic polymer, developed a water-in-oil emulsion formulation for their topical administration and compared the skin penetration routes with the same nanoparticles deposited as a colloidal suspension.	ferric oxide	52-62	modifier of Niemann Pick type C1	Mus musculus	79-82